Related Experiment Video
Updated: Jun 25, 2026

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
Published on: April 2, 2017
Self-limited acute hepatotoxicity caused by pegvisomant
A Soto Moreno1, R Guerrero Vázquez, E Venegas Moreno
1Department of Endocrinology and Nutrition, Instituto de Biomedicina de Sevilla (IBIS), Virgen del Rocio University Hospital, Seville, Spain. alfonsom.soto.sspa@juntadeandalucia.es
Abstract:
We present a case of acute severe hepatitis in a patient with acromegaly receiving combination therapy with somatostatin analogs and pegvisomant. Hepatitis resolved completely 18 weeks after diagnosis of hypertransaminasemia without discontinuation of therapy and with a close clinical and biochemical follow-up. In this case, despite the severity of the hepatitis, therapy could be continued as hypertransaminasemia was gradually decreasing after the maximum peak. We also review the literature on toxic hepatitis associated to pegvisomant therapy analyzing the etiology, clinical predisposing factors and natural evolution.
Related Concept Videos
Hepatic Encephalopathy
Drug toxicity: Idiosyncratic Reactions
Prevention of Further Absorption of Poison
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Allergic Reactions